---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-101292"
form_type: "8-K"
ticker: "IKT"
cik: "0001750149"
company_name: "Inhibikase Therapeutics, Inc."
filed_at: "2024-04-19T23:59:59+00:00"
generated_at: "2026-06-03T16:21:53.100319+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Inhibikase 201 trial ~75% enrolled; expects completion by mid-June 2024

## Summary
- 201 Trial (risvodetinib) ~75% enrolled, 30 patients left; enrollment completion expected mid-June 2024.
- Plan to initiate a 12-month extension study; requires additional capital.
- Pre-IND meeting with FDA for IkT-001Pro in PAH completed; pre-NDA for cancer indications held.
- Submitted grants to NINDS/NIH for biomarker development including new monoclonal antibody.
- Expects end-of-Phase 2 meeting with FDA by end of 2024.

## SEC filing metadata
- accession: 0001193125-24-101292
- form_type: 8-K
- ticker: IKT
- cik: 0001750149
- company_name: Inhibikase Therapeutics, Inc.
- filed_at: 2024-04-19T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750149/000119312524101292/0001193125-24-101292-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750149/000119312524101292/d826079d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-101292
- JSON: https://secwatch.observer/filing/0001193125-24-101292.json
- Plain text: https://secwatch.observer/filing/0001193125-24-101292.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.